Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Donner

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Journal of Diabetes Research|August 17, 2023
Predictors of Responsiveness to GLP-1 Receptor Agonists in Insulin-Treated Patients with Type 2 DiabetesColleen Gavigan, Thomas Donner
The Journal of Clinical Endocrinology and Metabolism|March 24, 2012
Update on insulin therapy for type 2 diabetesThomas Donner, Miguel Muñoz
American Family Physician|September 28, 2006
Tight control of type 1 diabetes: recommendations for patientsStephen Havas, Thomas Donner
Discovery Medicine|November 7, 2018
Hiding in plain sight: time to unlock autoimmune clues in human CD5+ B cells by using nextgen technologyRizwan Ahmed, Zahra Omidian, Thomas Donner, et al.
Discovery Medicine|April 27, 2016
B cell-targeted immunotherapy for type 1 diabetes: What can make it work?Abdel Rahim A Hamad, Rizwan Ahmed, Thomas Donner, et al.
Schizophrenia Research|November 23, 2007
Parental history of type 2 diabetes in patients with nonaffective psychosisEmilio Fernandez-Egea, Brian Miller, Miguel Bernardo, et al.
Frontiers in Immunology|July 19, 2012
The potential of Fas ligand (apoptosis-inducing molecule) as an unconventional therapeutic target in type 1 diabetesAbdel Rahim A R Hamad, Kristin Arcara, Sophia Uddin, et al.
Cellular Immunology|February 16, 2019
IL-17 and limits of successZahra Omidian, Rizwan Ahmed, Adebola Giwa, et al.
Cell|February 5, 2021
A reply to "TCR+/BCR+ dual-expressing cells and their associated public BCR clonotype are not enriched in type 1 diabetes"Rizwan Ahmed, Zahra Omidian, Adebola Giwa, et al.
Cytokine|December 8, 2014
Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapyAnkit Saxena, Sam Khosraviani, Sanjeev Noel, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Journal of Diabetes Research|August 17, 2023
Predictors of Responsiveness to GLP-1 Receptor Agonists in Insulin-Treated Patients with Type 2 DiabetesColleen Gavigan, Thomas Donner
The Journal of Clinical Endocrinology and Metabolism|March 24, 2012
Update on insulin therapy for type 2 diabetesThomas Donner, Miguel Muñoz
American Family Physician|September 28, 2006
Tight control of type 1 diabetes: recommendations for patientsStephen Havas, Thomas Donner
Discovery Medicine|November 7, 2018
Hiding in plain sight: time to unlock autoimmune clues in human CD5+ B cells by using nextgen technologyRizwan Ahmed, Zahra Omidian, Thomas Donner, et al.
Discovery Medicine|April 27, 2016
B cell-targeted immunotherapy for type 1 diabetes: What can make it work?Abdel Rahim A Hamad, Rizwan Ahmed, Thomas Donner, et al.
Schizophrenia Research|November 23, 2007
Parental history of type 2 diabetes in patients with nonaffective psychosisEmilio Fernandez-Egea, Brian Miller, Miguel Bernardo, et al.
Frontiers in Immunology|July 19, 2012
The potential of Fas ligand (apoptosis-inducing molecule) as an unconventional therapeutic target in type 1 diabetesAbdel Rahim A R Hamad, Kristin Arcara, Sophia Uddin, et al.
Cellular Immunology|February 16, 2019
IL-17 and limits of successZahra Omidian, Rizwan Ahmed, Adebola Giwa, et al.
Cell|February 5, 2021
A reply to "TCR+/BCR+ dual-expressing cells and their associated public BCR clonotype are not enriched in type 1 diabetes"Rizwan Ahmed, Zahra Omidian, Adebola Giwa, et al.
Cytokine|December 8, 2014
Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapyAnkit Saxena, Sam Khosraviani, Sanjeev Noel, et al.
Pageof 2